Icatibant ELISA Assay Portfolio for Pharmacokinetic and Immunogenicity Analysis

Icatibant is a synthetic peptide antagonist of the bradykinin B2 receptor, used for the acute treatment of hereditary angioedema attacks. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of localized swelling affecting the skin, gastrointestinal tract, and upper airway. These attacks are mediated by uncontrolled activation of the plasma contact system, leading to elevated bradykinin levels and increased vascular permeability. Icatibant provides rapid symptom relief by blocking bradykinin-mediated signaling at the B2 receptor. As a peptide therapeutic, Icatibant presents unique bioanalytical challenges. Its relatively small size compared to monoclonal antibodies, susceptibility to proteolytic degradation, and potential for immunogenicity necessitate specialized assays for pharmacokinetic and immunogenicity assessment. The Anti-Icatibant ELISA Kit and Icatibant ELISA Kit address these needs, providing targeted tools for measuring host antibodies against Icatibant and free drug concentrations in biological matrices. The clinical use of Icatibant has expanded patient autonomy through self-administration options, allowing individuals to treat attacks at onset. This therapeutic approach reduces the burden of emergency department visits and improves quality of life for patients with hereditary angioedema. However, the pharmacokinetic and immunogenicity profile of Icatibant must be carefully characterized to ensure consistent efficacy and safety across diverse patient populations.

Figure 1.Icatibant ELISA Assay Portfolio for Pharmacokinetic and Immunogenicity Analysis.

Molecular Pathway

The bradykinin pathway is central to the pathophysiology of hereditary angioedema. Bradykinin is a vasoactive peptide generated through the proteolytic cleavage of high-molecular-weight kininogen by plasma kallikrein. It binds to the B2 receptor on endothelial cells, triggering intracellular signaling events that increase vascular permeability and promote fluid extravasation into surrounding tissues. In patients with hereditary angioedema, deficiency or dysfunction of C1 inhibitor leads to uncontrolled plasma kallikrein activity and excessive bradykinin production. Icatibant is a selective antagonist of the bradykinin B2 receptor. By binding to the receptor with high affinity, Icatibant prevents bradykinin from activating downstream signaling pathways, thereby reducing vascular permeability and reversing the swelling associated with angioedema attacks. Its mechanism is distinct from therapies that target the contact system upstream, as it acts directly at the receptor level to antagonize the effects of bradykinin.

Therapeutic Applications

The primary clinical application of Icatibant is the acute treatment of hereditary angioedema attacks in adult patients. These attacks can be unpredictable, painful, and potentially life-threatening when involving the larynx or upper airway. By antagonizing the bradykinin B2 receptor, Icatibant reduces swelling and improves symptom resolution, offering patients a self-administered therapeutic option. Beyond hereditary angioedema, Icatibant has been investigated for other conditions mediated by bradykinin signaling, including certain forms of acquired angioedema, drug-induced angioedema, and inflammatory conditions where the kallikrein-kinin system contributes to disease pathology. In all these settings, reliable measurement of Icatibant exposure and anti-drug antibodies supports dose optimization, safety monitoring, and clinical development. The development of Icatibant biosimilars and follow-on peptide therapeutics requires rigorous bioanalytical comparison with reference products. The Icatibant ELISA Kit and Anti-Icatibant ELISA Kit provide standardized assays for pharmacokinetic equivalence and immunogenicity assessment, supporting the evidence packages needed for regulatory review and clinical adoption.

Research Utility

Product Portfolio

Anti-Icatibant ELISA Kit

The Anti-Icatibant ELISA Kit enables the quantitative detection of host anti-Icatibant antibodies in serum and plasma. The assay employs an Icatibant-coated microplate and an HRP-conjugated detection system, with results interpreted against appropriate controls. It supports immunogenicity assessment and risk monitoring for peptide therapeutic development.

Icatibant ELISA Kit

The Icatibant ELISA Kit is a sandwich-format enzyme immunoassay designed for the quantitative measurement of free Icatibant in human serum and plasma. It utilizes a microplate coated with an Icatibant-specific reactant and an HRP-conjugated detection probe, producing a signal proportional to the free peptide concentration. The assay is suitable for pharmacokinetic studies and bioanalytical method development.

Final Considerations

The Icatibant ELISA Kit and Anti-Icatibant ELISA Kit provide the bioanalytical capabilities needed to characterize drug exposure and immunogenicity throughout the product lifecycle. These assays support pharmacokinetic studies, clinical development, and the ongoing optimization of peptide-based therapies for bradykinin-mediated diseases. As peptide therapeutics continue to evolve, the need for sensitive and specific assays for free drug and anti-drug antibody measurement will grow. The Icatibant assay portfolio offers validated, ready-to-use solutions that address these analytical needs, enabling researchers to advance the understanding and application of bradykinin receptor antagonism in hereditary angioedema and related conditions.

The characterization of Icatibant pharmacokinetics and immunogenicity remains essential for both innovator and biosimilar development programs. By leveraging the Icatibant ELISA Kit and Anti-Icatibant ELISA Kit, researchers can generate robust datasets that inform dosing strategies, support regulatory submissions, and ultimately improve patient outcomes in the management of acute angioedema attacks. The successful clinical translation of Icatibant and similar peptide therapeutics depends on a thorough understanding of their exposure and immunogenicity profiles. The Icatibant ELISA Kit and Anti-Icatibant ELISA Kit deliver the sensitivity and specificity required for these assessments, supporting informed decision-making across preclinical discovery, clinical development, and post-market surveillance programs.

Icatibant ELISA Kits